Darios Getahun1,2, Michael J Fassett3, Steven J Jacobsen1, Anny H Xiang1, Harpreet S Takhar1, Deborah A Wing4,5, Morgan R Peltier6,7. 1. Department of Research and Evaluation, Kaiser Permanente, Southern California, Pasadena. 2. Department of Obstetrics, Gynecology, and Reproductive Sciences, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey. 3. Department of Obstetrics and Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California. 4. Department of Obstetrics and Gynecology, University of California, Irvine, California. 5. Korn Ferry, Los Angeles, California. 6. Department of Obstetrics and Gynecology, Winthrop University Hospital Research Institute, Winthrop University Hospital, Mineola, New York. 7. Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York.
Abstract
OBJECTIVE: This study aimed to determine if hyperemesis gravidarum (HG) is associated with autism spectrum disorder (ASD) risk, and how this association is influenced by race, ethnicity, sex, exposure timing, and medication used to treat it. STUDY DESIGN: This is a retrospective cohort study using records from 469,789 mother-child pairs who delivered at Kaiser Permanente Southern California (KPSC) hospital (1991-2014). Singleton-born children were followed longitudinally from 2 to 17 years of age. Clinical records were used to determine the diagnosis of HG and specialist-confirmed diagnosis of ASD. RESULTS: Children exposed to HG in-utero had higher rates of ASD than unexposed children (2.87 vs. 1.71/1,000 person-years; adjusted hazard ratio [adj.HR]: 1.53; 95% confidence interval [CI]: 1.37-1.70). Children exposed at first and second trimester of pregnancies were more likely to develop ASD; 1.58-fold (95% CI: 1.40-1.79), and 1.36-fold (95% CI: 1.05-1.75), respectively, compared with unexposed children. HG was associated with ASD for boys (adj.HR: 1.50; 95% CI: 1.33-1.70) and girls (adj.HR: 1.62; 95% CI: 1.28-2.05). HG was significantly associated with ASD risk in white and Hispanic children. The medications used to treat HG did not contribute to ASD risk. CONCLUSION: HG diagnosis is associated with ASD risk and may be helpful in identifying at-risk children who could benefit from enhanced surveillance and earlier diagnosis and intervention. Thieme. All rights reserved.
OBJECTIVE: This study aimed to determine if hyperemesis gravidarum (HG) is associated with autism spectrum disorder (ASD) risk, and how this association is influenced by race, ethnicity, sex, exposure timing, and medication used to treat it. STUDY DESIGN: This is a retrospective cohort study using records from 469,789 mother-child pairs who delivered at Kaiser Permanente Southern California (KPSC) hospital (1991-2014). Singleton-born children were followed longitudinally from 2 to 17 years of age. Clinical records were used to determine the diagnosis of HG and specialist-confirmed diagnosis of ASD. RESULTS:Children exposed to HG in-utero had higher rates of ASD than unexposed children (2.87 vs. 1.71/1,000 person-years; adjusted hazard ratio [adj.HR]: 1.53; 95% confidence interval [CI]: 1.37-1.70). Children exposed at first and second trimester of pregnancies were more likely to develop ASD; 1.58-fold (95% CI: 1.40-1.79), and 1.36-fold (95% CI: 1.05-1.75), respectively, compared with unexposed children. HG was associated with ASD for boys (adj.HR: 1.50; 95% CI: 1.33-1.70) and girls (adj.HR: 1.62; 95% CI: 1.28-2.05). HG was significantly associated with ASD risk in white and Hispanic children. The medications used to treat HG did not contribute to ASD risk. CONCLUSION: HG diagnosis is associated with ASD risk and may be helpful in identifying at-risk children who could benefit from enhanced surveillance and earlier diagnosis and intervention. Thieme. All rights reserved.
Authors: Nicholas L Syn; Shiao-Yng Chan; Elisha Wan Ying Chia; Wei Xin Ong; Desiree Phua; Shirong Cai; Lynette P C Shek; Yap-Seng Chong; Lourdes Mary Daniel; Birit F P Broekman; Keith M Godfrey; Michael J Meaney; Evelyn C Law Journal: Paediatr Perinat Epidemiol Date: 2020-06-23 Impact factor: 3.980
Authors: Caitlin R Dean; Hyke Bierma; Ria Clarke; Brian Cleary; Patricia Ellis; Roger Gadsby; Norah Gauw; Karen Lodge; Kimber MacGibbon; Marian McBride; Deirdre Munro; Catherine Nelson-Piercy; Margaret O'Hara; Helen Penny; Katherine Shorter; René Spijker; Jone Trovik; Emma Watford; Rebecca C Painter Journal: BMJ Open Date: 2021-01-15 Impact factor: 2.692
Authors: Richard Lindberg; Maria Lindqvist; Miles Trupp; Marie-Therese Vinnars; Malin L Nording Journal: Nutrients Date: 2020-11-04 Impact factor: 5.717